OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drugProactive Investors · Oct 6, 2026
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainGlobeNewsWire · Oct 6, 2026
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific ConferencesGlobeNewsWire · Sep 29, 2026
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026GlobeNewsWire · Sep 9, 2026
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare ConferenceGlobeNewsWire · Sep 8, 2026
OKYO Pharma Announces Purchase of Shares by Chief Scientific OfficerGlobeNewsWire · Jul 28, 2026OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 20, 2026 | -$0.08 | -$0.15 | Miss |
| Jan 30, 2026 | -$0.07 | -$0.01 | Beat |
| Jul 18, 2025 | -$0.05 | -$0.04 | Beat |
| Jan 29, 2025 | – | -$0.08 | |
| Oct 2, 2024 | – | -$0.08 | |
| May 13, 2024 | – | -$0.30 |